SEC Filings: As Zeltiq Aesthetics INC (ZLTQ) Stock Price Rose, Aisling Capital LLC Has Trimmed by $19.50 Million Its Position

SEC Filings: As Zeltiq Aesthetics INC (ZLTQ) Stock Price Rose, Aisling Capital LLC Has Trimmed by $19.50 Million Its Position

Dennis Purcell decreased its stake in Zeltiq Aesthetics Inc (ZLTQ) by 23.7% based on its latest 2016Q3 regulatory filing with the SEC. Aisling Capital Llc sold 500,000 shares as the company’s stock rose 41.95% with the market. The hedge fund run by Dennis Purcell held 1.61M shares of the health care company at the end of 2016Q3, valued at $63.13M, down from 2.11M at the end of the previous reported quarter. Aisling Capital Llc who had been investing in Zeltiq Aesthetics Inc for a number of months, seems to be less bullish one the $1.57 billion market cap company. The stock is up 1.13% or $0.46 hitting $41.17, despite the negative news. About 188,966 shares traded hands. Zeltiq Aesthetics Inc (NASDAQ:ZLTQ) has risen 38.56% since June 7, 2016 and is uptrending. It has outperformed by 31.14% the S&P500.

Aisling Capital Llc, which manages about $485.39 million US Long portfolio, upped its stake in Cynapsus Therapeutics Inc. by 100,000 shares to 1.12 million shares, valued at $45.10M in 2016Q3, according to the filing.

Aisling Capital is a healthcare focused investment company founded by Dennis Purcell. Presently, he holds the position of a senior advisor to the company with Steven Elms and Andrew Schiff as the managing partners. Aisling Capital usually prioritizes potential start-up companies and they hope to get bigger returns once such companies generate bigger earnings.

Insitutional Activity: The institutional sentiment increased to 1.47 in 2016 Q3. Its up 0.11, from 1.36 in 2016Q2. The ratio increased, as 28 funds sold all ZLTQ shares owned while 44 reduced positions. 36 funds bought stakes while 70 increased positions. They now own 43.43 million shares or 1.10% less from 43.91 million shares in 2016Q2. Lansdowne Prtnrs (Uk) Llp holds 0% or 7,455 shares in its portfolio. Texas Permanent School Fund holds 0.01% or 27,169 shares in its portfolio. Eam Investors Lc has invested 0.38% of its portfolio in Zeltiq Aesthetics Inc (NASDAQ:ZLTQ). Elk Creek Ptnrs Ltd Liability Corp owns 295,188 shares or 0.76% of their US portfolio. Commercial Bank Of America De has 0% invested in the company for 152,375 shares. Great West Life Assurance Comm Can owns 48,253 shares or 0.01% of their US portfolio. Rosenblum Silverman Sutton S F Incorporated Ca has invested 0.87% of its portfolio in Zeltiq Aesthetics Inc (NASDAQ:ZLTQ). Riverhead Cap Mgmt Limited Liability Com holds 1,300 shares or 0% of its portfolio. Suntrust Banks reported 5,143 shares or 0% of all its holdings. World Investors owns 3.12 million shares or 0.03% of their US portfolio. Lpl Financial Ltd Limited Liability Company last reported 0% of its portfolio in the stock. Arizona State Retirement holds 18,400 shares or 0.01% of its portfolio. Moreover, Mason Street Advisors Lc has 0.01% invested in Zeltiq Aesthetics Inc (NASDAQ:ZLTQ) for 7,342 shares. Pinebridge Invests Ltd Partnership has 0.01% invested in the company for 4,534 shares. Sei holds 0% of its portfolio in Zeltiq Aesthetics Inc (NASDAQ:ZLTQ) for 16,375 shares.

Insider Transactions: Since July 13, 2016, the stock had 0 buys, and 20 sales for $28.65 million net activity. $781,548 worth of shares were sold by Garcia Sergio on Monday, October 17. On Tuesday, December 13 Foley Mark J sold $440,789 worth of the stock or 10,000 shares. The insider Sullivan Keith J sold $264,058. The insider Lamm Carl sold $125,000. Hauser Bradley sold $111,978 worth of Zeltiq Aesthetics Inc (NASDAQ:ZLTQ) on Sunday, September 11. OBOYLE KEVIN C sold $300,612 worth of Zeltiq Aesthetics Inc (NASDAQ:ZLTQ) on Thursday, September 15. SCHIFF ANDREW N sold $18.20M worth of stock or 500,000 shares.

Analysts await Zeltiq Aesthetics Inc (NASDAQ:ZLTQ) to report earnings on March, 6. They expect $0.16 EPS, up 220.00% or $0.11 from last year’s $0.05 per share. ZLTQ’s profit will be $6.08 million for 64.17 P/E if the $0.16 EPS becomes a reality. After $0.12 actual EPS reported by Zeltiq Aesthetics Inc for the previous quarter, Wall Street now forecasts 33.33% EPS growth.

More recent Zeltiq Aesthetics Inc (NASDAQ:ZLTQ) news were published by: Finance.Yahoo.com which released: “ZELTIQ Aesthetics, Inc. Announces Commercial Leadership Transition” on January 09, 2017. Also Fool.com published the news titled: “Why Zeltiq Aesthetics Inc. Is Soaring Today” on November 10, 2016. Streetinsider.com‘s news article titled: “Form 3 Zeltiq Aesthetics Inc For: Jan 01 Filed by: Fitzgerald Mike” with publication date: January 10, 2017 was also an interesting one.

According to Zacks Investment Research, “Zeltiq Aesthetics Inc. is a medical technology company engaged in designing, development and commercialization of non-invasive procedures for the reduction of unwanted fat tissue. The Company offers CoolSculpting System and other products to the dermatologists, plastic surgeons, and aesthetic specialists in North America and internationally. Zeltiq Aesthetics Inc. is based in Pleasanton, California.”

Zeltiq Aesthetics Inc (NASDAQ:ZLTQ) Ratings Coverage

Out of 8 analysts covering Zeltiq Aesthetics (NASDAQ:ZLTQ), 7 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 88% are positive. Zeltiq Aesthetics has been the topic of 15 analyst reports since August 3, 2015 according to StockzIntelligence Inc. On Wednesday, August 26 the stock rating was maintained by William Blair with “Outperform”. The rating was maintained by Canaccord Genuity with “Buy” on Thursday, November 10. Griffin Securities upgraded the shares of ZLTQ in a report on Friday, January 22 to “Buy” rating. The rating was maintained by Maxim Group with “Buy” on Wednesday, October 28. JP Morgan maintained Zeltiq Aesthetics Inc (NASDAQ:ZLTQ) on Tuesday, August 9 with “Neutral” rating. The rating was initiated by Brean Capital on Wednesday, April 13 with “Buy”. The rating was maintained by Stifel Nicolaus with “Buy” on Wednesday, September 21. Leerink Swann maintained Zeltiq Aesthetics Inc (NASDAQ:ZLTQ) rating on Wednesday, October 28. Leerink Swann has “Outperform” rating and $42 price target. The stock has “Buy” rating given by Maxim Group on Wednesday, January 4. On Tuesday, September 1 the stock rating was maintained by Piper Jaffray with “Buy”.

ZLTQ Company Profile

ZELTIQ Aesthetics, Inc., incorporated on March 22, 2005, is a medical technology company. The Firm focuses on developing and commercializing products utilizing its controlled-cooling technology platform. The Company’s product, the CoolSculpting System, is designed to reduce stubborn fat bulges. The Firm sell its CoolSculpting system primarily to dermatologists, plastic surgeons, aesthetic specialists and obstetrics and gynecology (OBGYN) physicians. It also offers consumables, which are CoolSculpting procedure packs that are needed to perform procedures using its CoolSculpting system.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Leave a Reply

Be the First to Comment!

Notify of
avatar

wpDiscuz